What is Imunon, Inc. (IMNN) stock price today?

Imunon, Inc. (IMNN) is currently trading at $1.08, up 0.93% today.

What is IMNN P/E ratio?

Imunon, Inc.'s P/E ratio is -0.28. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is IMNN return on equity (ROE)?

Imunon, Inc.'s return on equity (ROE) is -314.89%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Imunon, Inc.'s market cap?

Imunon, Inc. has a market capitalization of $4.54M.

NASDAQ · Biotechnology

Imunon, Inc. (IMNN) Stock

$1.08 +0.93% NASDAQ: IMNN Healthcare

Valuation

Metric	Value
Price	$1.08
Market Cap	$4.54M
P/E Ratio	-0.28
P/B Ratio	1.60
P/S Ratio	0.00
EPS (TTM)	$-6.83
52-Week High	$5.40
52-Week Low	$1.02
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-314.89%
ROA	-98.17%
ROCE	-145.30%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	1.87
Current Ratio	2.20

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$1.0M	$1.0M	$0	$0	$0
Operating Profit	$-21.0M	$-25.0M	$-21.0M	$-19.0M	$-15.0M
Net Profit	$-21.0M	$-36.0M	$-20.0M	$-19.0M	$-14.0M
EPS	$-748.77	$-65.55	$-28.14	$-21.10	$-6.83
Op Margin	-4201.4%	-4984.3%	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$74.0M	$44.0M	$22.0M	$10.0M	$12.0M
Total Liabilities	$18.0M	$15.0M	$9.0M	$5.0M	$5.0M
Cash	$20.0M	$11.0M	$6.0M	$6.0M	$9.0M
Borrowings	$7.0M	$6.0M	$2.0M	$1.0M	$1.0M

Latest News

Imunon Says Ovarian Cancer Drug Trial Preliminary Results Show Deeper Antitumor Response MT Newswires · Jul 21, 2026 IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer GlobeNewswire · Jul 21, 2026 Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients Benzinga · Jul 21, 2026 OTC Markets Life Sciences Investor Forum: Stacy Lindborg, PhD, President, CEO, and Board Director, of Imunon with Zacks SCR’s David Bautz, PhD Zacks Small Cap Research · Jul 9, 2026 Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing GlobeNewswire · Jun 26, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-16.0M	$-23.0M	$-19.0M	$-19.0M	$-14.0M
Investing Cash Flow	$-30.0M	$8.0M	$11.0M	$10.0M	$-1.0M
Financing Cash Flow	$2.0M	$0	$0	$0	$0
Net Cash Flow	$8.0M	$-8.0M	$-12.0M	$0	$3.0M
Free Cash Flow	$-17.0M	$-23.0M	$-19.0M	$-19.0M	$-14.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.45
FCF Yield	-75703.77%
Quick Ratio	1.82
Interest Coverage	-191.99
Return 1Y	-72.08%
Return 3Y	-88.35%
Return 5Y	-99.06%

Ownership

Insiders Held5.08%

Institutions Held11.99%

Institutions Float Held12.63%

Institutional Holder	Shares	Report Date
Armistice Capital, LLC	348,330	2026-03-31
Vanguard Capital Management LLC	48,056	2026-03-31
Riverview Capital Advisers, LLC	34,364	2026-03-31
Geode Capital Management, LLC	33,211	2026-03-31
Vanguard Fiduciary Trust Co	13,269	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AEONAEON Biopharma, Inc.	$0.28	-10.97%	-0.08	$12.19M	0.00%
BOLTBolt Biotherapeutics, Inc.	$4.11	+12.60%	-0.22	$7.90M	0.00%
CINGCingulate Inc.	$4.89	+0.20%	-0.95	$65.86M	0.00%
CLRBCellectar Biosciences, Inc.	$1.45	+3.57%	-0.39	$11.59M	0.00%
COCPCocrystal Pharma, Inc.	$1.07	+0.00%	-1.49	$14.75M	0.00%

About Imunon, Inc.

Imunon, Inc. is led by CEO Stacy R. Lindborg, employs 25 people, headquartered in US, publicly traded since 1999.

Imunon, Inc. (IMNN) stock trades at $1.08 with a market capitalization of $4.54M. The stock is valued at a price-to-earnings (P/E) ratio of -0.28, price-to-book of 1.60, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.02 and $5.40, and currently trades 80.0% below its 52-week high.

On profitability, Imunon, Inc. generates a return on equity (ROE) of -314.89%, return on capital employed of -145.30%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides